Previous Close | 42.44 |
Open | 43.71 |
Bid | 43.04 x 1000 |
Ask | 43.57 x 800 |
Day's Range | 40.90 - 43.72 |
52 Week Range | 32.44 - 104.87 |
Volume | |
Avg. Volume | 1,207,456 |
Market Cap | 3.72B |
Beta (5Y Monthly) | 1.86 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -5.06 |
Earnings Date | Feb 22, 2023 - Feb 27, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 101.17 |
Subscribe to Yahoo Finance Plus to view Fair Value for NTLA
CRISPR editing firm Intellia Therapeutics was rated a new fundamental "overweight" (buy) by a sell-side firm Wednesday with a $67 price target. The On-Balance-Volume (OBV) line has been weak with a low just made in January. The weekly OBV line has struggled the past 18 months or so but may have made a low in January.
To many investors, gene editing sounds like the plot of a science fiction movie. The concept of being able to edit our DNA to cure genetic diseases is quite unbelievable, and the upside of gene editing to treat rare diseases is impressive. However, many gene editing stocks are making waves, looking to advance toward eradicating cancer and other serious illnesses. But ever since 2012, gene editing has been a reality, at least in terms of having the technology needed to edit genes. Don’t get me wr
Gene editing stocks present themselves as one of the more lucrative investments in the healthcare sector. Gene editing, a revolutionary take on the science of genetic engineering, has the potential to countless lives around the globe. By introducing genetic material into cells, scientists can correct genetic abnormalities in a way never seen before. With the potential for vast improvements, gene therapy and gene editing are promising modern biotechnology forms.InvestorPlace - Stock Market News,